Esther Pronker

Summary

Publications

  1. ncbi Risk in vaccine research and development quantified
    Esther S Pronker
    Vacceleron, Utrecht, The Netherlands
    PLoS ONE 8:e57755. 2013
  2. ncbi Development of new generation influenza vaccines: recipes for success?
    E S Pronker
    Vacceleron, Jenalaan 18c, 3584 CK Utrecht, The Netherlands
    Vaccine 30:7344-7. 2012
  3. ncbi Improving the quality of drug research or simply increasing its cost? An evidence-based study of the cost for data monitoring in clinical trials
    Esther Pronker
    Vacceleron, Leiden Department of Anaesthesiology, Leiden University Medical Centre, Leiden Centre for Human Drug Research, Leiden Profess Medical Consultancy BV, Heerhugowaard, The Netherlands
    Br J Clin Pharmacol 71:467-70. 2011
  4. ncbi The gold industry standard for risk and cost of drug and vaccine development revisited
    E S Pronker
    Vacceleron, Utrecht, The Netherlands
    Vaccine 29:5846-9. 2011

Detail Information

Publications4

  1. ncbi Risk in vaccine research and development quantified
    Esther S Pronker
    Vacceleron, Utrecht, The Netherlands
    PLoS ONE 8:e57755. 2013
    ..Although we find huge differences between the risk profiles for vaccine and NCE; vaccines outperform NCE when it comes to development timelines...
  2. ncbi Development of new generation influenza vaccines: recipes for success?
    E S Pronker
    Vacceleron, Jenalaan 18c, 3584 CK Utrecht, The Netherlands
    Vaccine 30:7344-7. 2012
    ..Faced with an attrition rate estimated around 80%, key opinion leaders were interviewed with the question: is there a recipe for success?..
  3. ncbi Improving the quality of drug research or simply increasing its cost? An evidence-based study of the cost for data monitoring in clinical trials
    Esther Pronker
    Vacceleron, Leiden Department of Anaesthesiology, Leiden University Medical Centre, Leiden Centre for Human Drug Research, Leiden Profess Medical Consultancy BV, Heerhugowaard, The Netherlands
    Br J Clin Pharmacol 71:467-70. 2011
    ..Guidelines or legislations relating to clinical data management are of limited value and no study has yet demonstrated its effectiveness...
  4. ncbi The gold industry standard for risk and cost of drug and vaccine development revisited
    E S Pronker
    Vacceleron, Utrecht, The Netherlands
    Vaccine 29:5846-9. 2011
    ..Published cumulative success rates range from 7% to 78% and investments calculations span US$ 0.8 to 1.7 Billion. Obviously this disserves further clarification?..